Paula
Rodríguez Otero
Consultora Médica
![Foto de Paula](/img/nophoto.png)
![Foto de University of Turin](/img/noimage_org.png)
University of Turin
Turín, ItaliaPublicacións en colaboración con investigadores/as de University of Turin (9)
2024
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313
2023
2022
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Melphalan flufenamide for relapsed/refractory multiple myeloma
Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423
2020
-
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1850-1859
2019
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557